Eli Lilly Stock Surges Past $1,000 Ahead of Earnings

Eli Lilly and Company is facing increasing pressure from Wall Street analysts and investors to execute a stock split after its share price consistently traded above $1,000. The company recently became the first pharmaceutical firm to reach a $1 trillion market capitalization, driven by the commercial success of its GLP-1 diabetes drug Mounjaro and the obesity treatment Zepbound.

Although the company has not officially announced a split, investors argue that reducing the price per share would make the stock more affordable and attract a broader base of new shareholders without impacting the company's fundamental valuation.

Market focus now shifts to the company's second-quarter earnings report scheduled for August 5. Investors anticipate a 32% year-over-year increase in sales and are awaiting new data regarding Foundayo, a weight-loss pill currently in development.